Literature DB >> 11920475

Prognostic factors in patients with thick cutaneous melanoma (> 4 mm).

Elizabeth Zettersten1, Richard W Sagebiel, James R Miller, Sreedhar Tallapureddy, Stanley P L Leong, Mohammed Kashani-Sabet.   

Abstract

BACKGROUND: The current study was conducted to examine the role of multiple clinical and histologic factors in the prognostic assessment of patients with thick primary melanoma (> 4 mm, classified as T4).
METHODS: A retrospective analysis was performed in 329 patients with T4 cutaneous melanomas who were seen at the University of California at San Francisco Melanoma Center between 1978 and 2000. Fourteen histopathologic features were recorded prospectively by a single dermatopathologist. In addition, 9 clinical factors were analyzed.
RESULTS: Several histologic factors were found to have a significant impact on the survival of patients with T4 melanoma. On univariate analysis, tumor thickness, ulceration, mitotic rate, microsatellites, vascular involvement, and histogenetic type of the primary tumor all were found to have a significant impact on the overall survival rate. Regional lymph node involvement reduced the overall survival of T4 patients dramatically. The 5-year overall survival of patients with lymph node-negative T4 disease was 61%, compared with 30% for those with lymph node-positive disease. When lymph node status was taken into account, tumor thickness, vascular involvement, and ulceration all remained independent predictors of overall survival on multivariate Cox regression analysis. Neither age, gender, nor anatomic location appeared to affect the recurrence-free or overall survival rates.
CONCLUSIONS: Patients with thick primary cutaneous melanomas (> 4 mm) comprise a heterogeneous group. The presence or absence of lymph node involvement, vascular involvement, and ulceration appears to result in significantly divergent overall survival rates in this patient cohort. Consideration of these factors has important implications in the management of patients with T4 melanoma. Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10326

Entities:  

Mesh:

Year:  2002        PMID: 11920475

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Unusual histologic and clinical variants of melanoma: implications for therapy.

Authors:  A Neil Crowson; Cynthia Magro; Martin C Mihm
Journal:  Curr Treat Options Oncol       Date:  2006-05

Review 2.  Unusual histologic and clinical variants of melanoma: implications for therapy.

Authors:  A Neil Crowson; Cynthia Magro; Martin C Mihm
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

3.  Giant cutaneous melanomas: evidence for primary tumour induced dormancy in metastatic sites?

Authors:  William W Tseng; Judy A Doyle; Sheilagh Maguiness; Andrew E Horvai; Mohammed Kashani-Sabet; Stanley P L Leong
Journal:  BMJ Case Rep       Date:  2009-10-05

4.  Stage III thick (>4.0 mm) lower extremity melanoma: is timing of lymph node involvement a prognostic factor?

Authors:  Krzysztof Herman; Wojciech M Wysocki; Piotr Skotnicki; Jacek Tabor; Elebieta Luczyńska; Andrzej L Komorowski
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

5.  Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis.

Authors:  Meng Qian; Michelle W Ma; Nathaniel H Fleming; Daniel J Lackaye; Eva Hernando; Iman Osman; Yongzhao Shao
Journal:  Melanoma Res       Date:  2013-12       Impact factor: 3.599

Review 6.  Patient with giant upper limb melanoma presenting to a UK plastic surgery unit: differentials and experience of management.

Authors:  Calum Sinclair Honeyman; Paul Wilson
Journal:  BMJ Case Rep       Date:  2016-02-02

7.  Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma?

Authors:  Daniela Göppner; Martin Leverkus
Journal:  J Skin Cancer       Date:  2011-10-11

8.  Desmoplastic Melanoma: Clinical Behavior and Management Implications.

Authors:  Collier S Pace; Jyoti P Kapil; Luke G Wolfe; Brian J Kaplan; James P Neifeld
Journal:  Eplasty       Date:  2016-01-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.